

Wei Zhang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1341194/wei-zhang-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

9,400
citations

22
h-index

45
g-index

45
ext. papers

12,765
ext. citations

11.6
avg. IF

4.35
L-index

#	Paper	IF	Citations
44	Integrated analysis of the prognostic and oncogenic roles of OPN3 in human cancers.. <i>BMC Cancer</i> , 2022 , 22, 187	4.8	0
43	Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes.. <i>Frontiers in Oncology</i> , 2022 , 12, 714338	5.3	0
42	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5691	6.3	2
41	Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples. <i>Cancer Science</i> , 2021 ,	6.9	4
40	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021 , 19, 1-12	6.5	103
39	A potentially effective drug for patients with recurrent glioma: sermorelin. <i>Annals of Translational Medicine</i> , 2021 , 9, 406	3.2	1
38	Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. <i>British Journal of Cancer</i> , 2021 , 125, 255-264	8.7	0
37	neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival. <i>BMC Bioinformatics</i> , 2021 , 22, 382	3.6	1
36	A novel DNA repair-related nomogram predicts survival in low-grade gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2021 , 27, 186-195	6.8	1
35	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021 , 499, 60-72	7.9	61
34	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. <i>CNS Neuroscience and Therapeutics</i> , 2021 , 27, 617-628	6.8	2
33	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. <i>OncoTargets and Therapy</i> , 2021 , 14, 1707-1718	4.4	3
32	Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. <i>Frontiers in Genetics</i> , 2021 , 12, 741325	4.5	
31	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.. <i>Frontiers in Immunology</i> , 2021 , 12, 800928	8.4	2
30	Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. <i>Journal of Pathology</i> , 2020 , 251, 272-283	9.4	19
29	Classification of diffuse lower-grade glioma based on immunological profiling. <i>Molecular Oncology</i> , 2020 , 14, 2081-2095	7.9	24
28	Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. <i>Cancers</i> , 2020 , 12,	6.6	7

27	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. <i>Cancer Medicine</i> , 2020 , 9, 1955-1965	4.8	5
26	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. <i>Scientific Reports</i> , 2020 , 10, 16218	4.9	5
25	A novel methylation signature predicts radiotherapy sensitivity in glioma. <i>Scientific Reports</i> , 2020 , 10, 20406	4.9	2
24	Redox Regulator Is Associated With Tumor Immunity in Glioma. <i>Frontiers in Immunology</i> , 2020 , 11, 580934	4.4	8
23	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. <i>Frontiers in Immunology</i> , 2020 , 11, 581209	8.4	10
22	Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy. <i>OncoTargets and Therapy</i> , 2019 , 12, 10263-10273	4.4	11
21	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
20	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018 , 23, 255-269.e4	10.6	112
19	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. <i>Cell Death and Disease</i> , 2018 , 9, 1190	9.8	27
18	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. <i>Cell</i> , 2018 , 175, 1665-1678.e18	56.2	125
17	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. <i>OncoImmunology</i> , 2017 , 6, e1328339	7.2	74
16	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016 , 164, 550-63	56.2	1140
15	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. <i>OncoImmunology</i> , 2016 , 5, e1196310	7.2	116
14	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016 , 375, 263-273	9.9	253
13	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015 , 372, 2481-98	59.2	1828
12	Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. <i>Acta Neuropathologica</i> , 2015 , 130, 587-97	14.3	46
11	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. <i>Oncotarget</i> , 2015 , 6, 36643-51	3.3	32
10	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. <i>Genome Research</i> , 2014 , 24, 1765-73	9.7	237

9	A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 3538-43	11.5	70
8	Multidimensional analysis of gene expression reveals TGFB111-induced EMT contributes to malignant progression of astrocytomas. <i>Oncotarget</i> , 2014 , 5, 12593-606	3.3	31
7	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
6	Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme. <i>CNS Neuroscience and Therapeutics</i> , 2013 , 19, 714-20	6.8	17
5	Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. <i>Cancer Letters</i> , 2013 , 328, 120-5	9.9	53
4	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. <i>Cancer</i> , 2013 , 119, 814-24	6.4	74
3	Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. <i>PLoS ONE</i> , 2012 , 7, e30339	3.7	99
2	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. <i>Neuro-Oncology</i> , 2012 , 14, 1432-40	1	133
1	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients		8